(1R,3S)-3-(1H-Benzo[d]imidazol-2-yl)-1,2,2-tri-methyl-cyclo-pentane-1-carb-oxy-lic acid as a new anti-diabetic active pharmaceutical ingredient.
Sergiy M KovalenkoIrina S KonovalovaSergiy I MerzlikinVladimir P ChuevDmitry V KravchenkoPublished in: Acta crystallographica. Section E, Crystallographic communications (2020)
The chiral title compound, C16H20N2O2, which can be used for producing active pharmaceutical ingredients for treatment of type 2 pancreatic diabetes and other pathologies dependent on insulin resistance, was prepared from (1R,3S)-camphoric acid and o-phenyl-enedi-amine. It crystallized from an ethanol solution in the chiral monoclinic P21 space group. The five-membered ring adopts a twisted conformation with the methyl-substituted C atoms displaced by -0.273 (5) and 0.407 (5) Å from the mean plane through the other three atoms. In the crystal, mol-ecules are linked by O-H⋯N hydrogen bonds, forming chains along the a-axis direction. Hirshfeld surface analysis and two-dimensional fingerprint plots were used to analyze the inter-molecular contacts present in the crystal.
Keyphrases
- type diabetes
- insulin resistance
- crystal structure
- cardiovascular disease
- capillary electrophoresis
- glycemic control
- solid state
- metabolic syndrome
- ionic liquid
- adipose tissue
- molecular docking
- high fat diet
- polycystic ovary syndrome
- combination therapy
- wound healing
- single molecule
- high fat diet induced
- smoking cessation